Search Results
Your search for ,FAm matches 242 pages
Showing 51 - 100HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
Expert Point of View: Valentina Guarneri, MD
Invited discussant of the HER2CLIMB-02 trial, Valentina Guarneri, MD, of Padeva Istituto Oncologica Veneto, Italy, hailed these results as important, especially for patients with HER2-positive breast cancer and brain metastases. However, she noted, “HER2CLIMB-02 is not likely to challenge the...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
Invited discussant of TROPION-Lung01, Sarat Chandarlapaty, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, was cautiously optimistic about this new treatment option. “Dato-DXd [datopotamab deruxtecan] has a benefit over standard-of-care docetaxel in the second-line setting. There...
Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Background...
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
Invited discussant of TROPION-Lung01, Sarat Chandarlapaty, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, was cautiously optimistic about this new treatment option. “Dato-DXd [datopotamab deruxtecan] has a benefit over standard-of-care docetaxel in the second-line setting. There...
Expert Point of View: Helena Linardou, MD, PhD
Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...
Breast Cancer 2022–2023 Almanac
The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...
Expert Point of View: Neelima Vidula, MD
Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead
Jame Abraham, MD, FACP, has been in the field of oncology for more than 2 decades, he and says this is both one of the most exhilarating and challenging times in cancer care. “What excites me the most are the innovations in treatment that are literally transforming the lives of our patients and...
DESTINY-Lung02: T-DXd for HER2-Mutant Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Goto et al, primary results of the phase II DESTINY-Lung02 trial have shown activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (NSCLC) previously treated with platinum-containing...
New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments
New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...
Expert Point of View: Barbara Pistilli, MD
The invited discussant of the study by Bar et al, Barbara Pistilli, MD, Head of the Breast Cancer Unit at Gustave Roussy Cancer Center, Villejuif, France, noted that third-generation antibody-drug conjugates, such as fam-trastuzumab deruxtecan-nxki (T-DXd), are showing activity across a wide range ...
HER2-Low Status Is ‘Dynamic’ for Patients With Triple-Negative Breast Cancer
The probability of obtaining a HER2-low test result increases with the number of biopsies performed, according to a study of more than 500 biopsy samples in patients with triple-negative breast cancer. For patients originally labeled as having no HER2 expression (HER2 0), each successive biopsy...
ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer
In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
Expert Point of View: Gustavo Werutsky, MD and Lisa A. Carey, MD, ScM, FASCO
Invited discussant Gustavo Werutsky, MD, emphasized that health-related quality of life was consistently maintained in all phase III trials with fam-trastuzumab deruxtecan-nxki (T-DXd) in the metastatic breast cancer setting. Dr. Werutsky also highlighted the need for real-world data to understand...
Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer
Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: DESTINY-Gastric02
In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a...
Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan
Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of HER2-expressing solid tumors. This agent showed an...
Study Finds T-DXd Effectively Treats HER2-Expressing Cancers, Regardless of Tumor Location
According to the findings of the international phase II DESTINY-PanTumor02 study presented by Funda Meric-Bernstam, MD, and colleagues at the 2023 ASCO Annual Meeting, fam-trastuzumab deruxtecan-nxki (T-DXd) is an effective treatment option for people with difficult-to-treat, HER2-expressing solid...
Trastuzumab Deruxtecan vs Physician’s Choice in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine
As reported in The Lancet by André et al, the phase III DESTINY-Breast02 trial has shown improved progression-free survival with fam-trastuzumab deruxtecan-nxki vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received prior ado-trastuzumab...
T-DXd in HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
In a Japanese phase II trial (STATICE) reported in the Journal of Clinical Oncology, Nishikawa et al found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed activity in patients with HER2-expressing advanced or recurrent uterine carcinosarcoma. Study Details In the multicenter trial, 32 evaluable ...
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
Expert Point of View: Maryam B. Lustberg, MD, MPH
Maryam B. Lustberg, MD, MPH, Chief of Breast Medical Oncology at Yale Cancer Center, New Haven, shared her thoughts on TROPiCS-02 with The ASCO Post. “The progression-free survival and overall survival results of the phase III TROPiCS-02 trial position sacituzumab govitecan-hziy as an important...
Challenges of Accurately Identifying HER2-Low Breast Cancers
The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...
Updated Results of DESTINY-Breast03: T-DXd vs T-DM1 for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or...
Expert Point of View: Jason Aboudi Mouabbi, MD
“These results [from the TRIO-US B-12 TALENT trial] are exciting and impressive in HER2-low, hormone receptor–positive patients. The authors were testing the waters and got a positive signal,” said Jason Aboudi Mouabbi, MD, a medical oncologist at MD Anderson Cancer Center, Houston. “The beauty of ...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Expert Point of View: Neelima Vidula, MD
Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab...
Sara A. Hurvitz, MD, on Updated Survival Results on T-DXd vs T-DM1 in Metastatic Breast Cancer
Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with...
Expert Point of View: Véronique Diéras, MD
The invited discussant of the phase I/II study of patritumab deruxtecan (HER3-DXd) was Véronique Diéras, MD, of the Eugène Marquis Centre, Rennes, France. She commented that HER3-DXd showed promising activity across breast cancer subtypes with heavily pretreated metastatic breast cancer. She...
Study Finds Patritumab Deruxtecan Active in HER3-Expressing Metastatic Breast Cancer
The HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) showed activity in patients with heavily pretreated HER3-expressing metastatic breast cancer in a phase I/II study. Ian E. Krop, MD, PhD, Associate Director, Yale Cancer Center, New Haven, Connecticut, presented these...
T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02
Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1), according to results from ...
T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03
Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
T-DXd in Pretreated Patients With HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
As reported in the Journal of Clinical Oncology by Yamaguchi et al, an exploratory cohort analysis in a Japanese/South Korean phase II trial (DESTINY-Gastric01) indicated that fam-trastuzumab deruxtecan-nxki (TDX-d) showed activity in previously treated—but anti-HER2 treatment–naive—patients with...
